These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 28938590)

  • 1. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions.
    Fu C; Gombos DS; Lee J; George GC; Hess K; Whyte A; Hong DS
    Oncotarget; 2017 Aug; 8(35):58709-58727. PubMed ID: 28938590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular toxicity of targeted therapies.
    Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
    J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
    Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
    Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Known and novel ocular toxicities of biologics, targeted agents, and traditional chemotherapeutics.
    Kunkler AL; Binkley EM; Mantopoulos D; Hendershot AJ; Ohr MP; Kendra KL; Davidorf FH; Cebulla CM
    Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1771-1781. PubMed ID: 31098752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ocular toxicity of investigational anti-cancer drugs in early phase clinical trials.
    Takamizawa S; Katsuya Y; Chen YN; Mizuno T; Koyama T; Sudo K; Yoshida T; Kondo S; Iwasa S; Yonemori K; Shimizu T; Yamamoto N; Suzuki S
    Invest New Drugs; 2023 Feb; 41(1):173-181. PubMed ID: 36471215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
    Ho WL; Wong H; Yau T
    Acta Ophthalmol; 2013 Nov; 91(7):604-9. PubMed ID: 22970709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen-associated eye disease. A review.
    Nayfield SG; Gorin MB
    J Clin Oncol; 1996 Mar; 14(3):1018-26. PubMed ID: 8622006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermatologic Toxicity Occurring During Anti-EGFR Monoclonal Inhibitor Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review.
    Lacouture ME; Anadkat M; Jatoi A; Garawin T; Bohac C; Mitchell E
    Clin Colorectal Cancer; 2018 Jun; 17(2):85-96. PubMed ID: 29576427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis.
    Niraula S; Amir E; Vera-Badillo F; Seruga B; Ocana A; Tannock IF
    J Clin Oncol; 2014 Nov; 32(32):3634-42. PubMed ID: 25267757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of ocular toxicities associated with novel anticancer therapeutics: What the oncologist needs to know.
    Ali A; Shah AA; Jeang LJ; Fallgatter KS; George TJ; DeRemer DL
    Cancer Treat Rev; 2022 Apr; 105():102376. PubMed ID: 35303547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular adverse events of molecularly targeted agents approved in solid tumours: a systematic review.
    Huillard O; Bakalian S; Levy C; Desjardins L; Lumbroso-Le Rouic L; Pop S; Sablin MP; Le Tourneau C
    Eur J Cancer; 2014 Feb; 50(3):638-48. PubMed ID: 24256808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success.
    Cazzaniga ME; Danesi R; Girmenia C; Invernizzi P; Elvevi A; Uguccioni M;
    Breast Cancer Res Treat; 2019 Aug; 176(3):483-494. PubMed ID: 31065872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.
    Abdel-Rahman O; Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):387-394. PubMed ID: 28277102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laser-assisted cataract surgery versus standard ultrasound phacoemulsification cataract surgery.
    Day AC; Gore DM; Bunce C; Evans JR
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD010735. PubMed ID: 27387849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular Toxicity of Tyrosine Kinase Inhibitors.
    Davis ME
    Oncol Nurs Forum; 2016 Mar; 43(2):235-43. PubMed ID: 26906134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular Adverse Events Associated with Antibody-Drug Conjugates in Human Clinical Trials.
    Eaton JS; Miller PE; Mannis MJ; Murphy CJ
    J Ocul Pharmacol Ther; 2015 Dec; 31(10):589-604. PubMed ID: 26539624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac toxicities of anticancer treatments: chemotherapy, targeted therapy and immunotherapy.
    Zarifa A; Albittar A; Kim PY; Hassan S; Palaskas N; Iliescu C; Durand JB; Lopez-Mattei J
    Curr Opin Cardiol; 2019 Jul; 34(4):441-450. PubMed ID: 31082852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Punctal occlusion for dry eye syndrome.
    Ervin AM; Law A; Pucker AD
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006775. PubMed ID: 28649802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular surface complications of local anticancer drugs for treatment of ocular tumors.
    Moon J; Choi SH; Lee MJ; Jo DH; Park UC; Yoon SO; Woo SJ; Oh JY
    Ocul Surf; 2021 Jan; 19():16-30. PubMed ID: 33238207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular side effects of biological agents in oncology: what should the clinician be aware of?
    Hager T; Seitz B
    Onco Targets Ther; 2013 Dec; 7():69-77. PubMed ID: 24391443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.